Phibro Animal Health Corporation announced on December 18 2025 that Jack Bendheim will transition from his role as Chief Executive Officer and President to Executive Chairman, while his son Daniel (Dani) Bendheim will assume the CEO and President positions effective July 1 2026. Jack Bendheim, who joined Phibro in 1969 and became President in 1988, has steered the company through a period of rapid expansion, including the acquisition of Zoetis’s medicated feed additives and water‑soluble product portfolio in October 2024. Daniel, who has been with Phibro since 1997 and has served as Vice President of Business Development, Chief Transformation Officer, Executive Vice President of Corporate Strategy and President of Performance Products, will take over day‑to‑day operations and continue the company’s growth strategy.
Jack Bendheim’s 57‑year association with Phibro began in 1969, but his tenure as President started in 1988 and he was appointed CEO in March 2014. Under his leadership, Phibro grew its net sales from $1.0 billion in 2014 to $1.296 billion in FY2025, a 27% year‑over‑year increase, and expanded its product portfolio through strategic acquisitions. Daniel’s experience in business development and transformation has positioned him to drive the Phibro Forward initiative, a company‑wide program focused on operational efficiency, margin expansion, and cultural engagement.
The October 2024 acquisition of Zoetis’s MFA portfolio for approximately $350 million added a high‑margin product line that contributed to the 39% year‑over‑year rise in Q4 FY2025 net sales to $378.7 million. The integration of the Zoetis portfolio has been largely cost‑neutral, with incremental revenue offsetting modest increases in raw material costs, thereby supporting the company’s adjusted diluted EPS of $0.57, a 39% year‑over‑year increase that beat consensus estimates of $0.52 by $0.05 (9.6%). The earnings beat was driven by disciplined cost management and a favorable mix shift toward higher‑margin performance products.
Phibro reported Q4 FY2025 results that exceeded analyst expectations across revenue and earnings. Net sales rose 39% to $378.7 million, driven by a 45% increase in performance product sales and a 30% rise in feed additive sales, while adjusted diluted EPS of $0.57 beat the consensus of $0.52 by $0.05. The company guided for full‑year FY2026 net sales of $1.425 billion to $1.475 billion, up from the prior guidance of $1.35 billion to $1.40 billion, and adjusted EBITDA of $225 million to $235 million, reflecting confidence in continued margin expansion and the ongoing integration of the Zoetis portfolio.
Daniel Bendheim emphasized that the Phibro Forward initiative will accelerate operational efficiencies and support the company’s margin expansion goals. “We are building a culture of continuous improvement and leveraging our global procurement network to drive cost savings,” he said. Jack Bendheim added, “I am confident that Daniel’s deep knowledge of our business and his track record of transformation will guide Phibro into its next growth phase.” The transition signals continuity while injecting fresh leadership to sustain momentum in a competitive animal‑health market.
Investors and analysts have responded positively to the leadership transition, noting that the company’s strong Q4 results, robust guidance, and clear strategic focus on the Phibro Forward initiative reinforce confidence in Phibro’s long‑term growth prospects.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.